Radiation therapy for early stage (I/II) non-small cell lung cancer

Frontiers of Radiation Therapy and Oncology

Volumn 42, Issue , 2010, Pages 87-93

  Jeremic, Branislav ^a   Casas, Francesc ^b   Wang, Luhua ^c   Perin, Branislav ^d  

^a INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

^b Clinic University Hospital   (Spain)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d Institute of Lung Diseases   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; CANCER SURVIVAL; EARLY CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; REVIEW; TREATMENT INDICATION;

CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77949400790     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000262464     Document Type: Review

References (39)

1. Jeremic B, Classen J, Bamberg M: Radiation therapy alone in technically operable, medically inoperable early stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:119-130.
2. Zhang HX, Yin WB, Zhang LJ: Curative radiotherapy of early operable non-small cell lung cancer. Radiother Oncol 1989;14:89-94.
3. Morita K, Fuwa N, Suzuki Y: Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: retrospective analysis of 149 patients. Radiother Oncol 1997;42:31-36.
4. Jeremic B, Shibamoto Y, Acimovic LJ, Milisavljevic S: Hyperfractionated radiotherapy alone for clinical stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1997;38:521-525.
5. Jeremic B, Shibamoto Y, Acimovic LJ, Milisavljevic S: Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer. Radiother Oncol 1999;51:141-145.
6. Cheung PCF, Mackillop WJ, Dixon P: Involvedfield radiotherapy alone for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2000;48:703-710.
7. Sandler HM, Curran WJ Jr, Turrisi AT III: The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1990;19:9-13.
8. Kaskowitz L, Graham MV, Emami B: Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993;27:517-523.
9. Krol ADG, Aussems P, Noordijk EM: Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation? Int J Radiat Oncol Biol Phys 1996;34:297-302.
10. Sibley GS, Jamieson TA, Marks LB: Radiotherapy alone for medically inoperable stage I non-small cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 1998;40:149-154.
11. Slotman BJ, Karim ABMF: Curative radiotherapy for technically operable stage I nonsmall cell lung cancer. Int JRadiat Oncol Biol Phys 1994;29:33-37.
12. Noordijk EM, van den Poest Clement E, Hermans J: Radiotherapy as an alternative to surgery in elderly patients with respectable lung cancer. Radiother Oncol 1988;13 :83-89.
13. Slotman BJ, Antonisse IE, Njo KH: Limited field irradiation in early stage (T1-2 N0) non-small cell lung cancer. Radiother Oncol 1996;41:41-44.
14. Mountain CF: A new international staging system for lung cancer. Chest 1986;89:225S-233S.
15. Mountain CF: Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
16. Gauden S, Ramsay J, Tripcony L: The curative treatment by radiotherapy alone of stage I nonsmall cell carcinoma of the lung. Chest 1995;108: 1278-1282.
17. Dosoretz DE, Katin MJ, Blitzer PH: Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys 1992;25:3-9.
18. Hayakawa K, Mitsuhashi N, Nakajima N: Radiation therapy for stage III epidermoid carcinoma of the lung. Lung Cancer 1992;8:213-224.
19. Rosenthal SA, Curran WJ Jr, Herbert SH: Clinical stage II non-small cell lung cancer treated with radiation therapy alone: the significance of clinically staged ipsilateral hilar adenopathy (N1 disease). Cancer 1992;70:3410-3417.
20. Dosoretz DE, Galmarini D, Rubenstein JH: Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys 1993;27:507-516.
21. Ono R, Egawa S, Suemasu K: Radiotherapy in inoperable stage I lung cancer. Jpn J Clin Oncol 1991;21:125-128.
22. Jeremic B: Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in non-small cell lung cancer (NSCLC): enough to convert no-elective into elective nodal irradiation (ENI)? Radiother Oncol 2004;71:123-125.
23. Jeremic B: Low incidence of isolated nodal failures after involved field radiation therapy (IFRT) for nonsmall cell lung cancer (NSCLC): blinded by the light? J Clin Oncol 2007;25:5543-5545.
24. Belderbos JSA, Kepka L, Kong FM, Martel MK, Videtic GMM, Jeremic B: Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer. Non-Small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys 2008;72: 335-342.
25. Jeremic B, Shibamoto Y, Milicic B, Dagovic A, Nikolic N, Aleksandrovic J, Acimovic L, Milisavljevic S: Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy (Hfx RT) alone. Lung Cancer 2003;40:317-323.
26. Gauden SJ, Tripcony L: The curative treatment by radiation therapy alone of stage I non-small cell lung cancer in a geriatric population. Lung Cancer 2001;32:71-79.
27. Hayakawa K, Mitsuhashi N, Katano S: High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer. Lung Cancer 2001;32:81-88.
28. Holsti LB, Vuorinen P: Radiation reaction in the lung after continuous and split-course megavoltage radiotherapy of bronchial carcinoma. Br J Radiol 1967;40:280-284.
29. Moss WT, Haddy FJ, Sweany SK. Some factors altering the severity of acute radiation pneumonitis: variation with cortisone, heparin, and antibiotics. Radiology 1960;75:50-54.
30. Rubin P, Casarett GW: Clinical Radiation Pathology. Philadelphia, Saunders, 1968, pp 423-470.
31. Mah K, Van Dyk J, Keane T: Acute radiationinduced pulmonary damage: a clinical study on the response to fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1987;13:179-188.
32. McDonald S, Rubin P, Phillips TL: Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995;31:1187-1203.
33. Braun SR, Do Poco GA, Olson CE: Low-dose radiation pneumonitis. Cancer 1975;35:1322-1324.
34. Prasad SC: Relation between tolerance dose and treatment field size in radiation therapy. Med Phys 1978;5:430-433.
35. Garipagaoglu M, Munley MT, Hollis D: The effect of patient specific factors on radiation induced regional lung injury. Int J Radiat Oncol Biol Phys 1999;45:3331-3338.
36. Cox JD, Pajak TF, Asbell S: Interruptions of highdose radiation therapy decrease long-term survival of favourable patients with unresectable non-small cell carcinoma of the lung: analysis of 1,244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1993;27:493-498.
37. Chen M, Jiang G-L, Fu X-L: The impact of overall treatment time on outcomes in radiation therapy for nonsmall cell lung cancer. Lung Cancer 2000; 28:11-19.
38. Jeremic B, Shibamoto Y, Acimovic L, Nikolic N, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G: Second cancers occurring in patients with early stage non-small cell lung cancer treated with chest radiation therapy alone. J Clin Oncol 2001; 19:1056-1063.
39. Jeremic B, Milicic B , Acimovic L, Milisavljevic S: Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early stage (I/II) non-small cell lung cancer (NSCLC). Long -term results of a phase II study. J Clin Oncol 2005;23:6873-6880.